<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background and Purpose: We performed a combination of prespecified and exploratory subgroup analyses to detect any treatment differences among various baseline subgroups in the <z:chebi fb="8" ids="10033">Warfarin</z:chebi>-Aspirin Recurrent <z:hpo ids='HP_0001297'>Stroke</z:hpo> Study (WARSS) cohort </plain></SENT>
<SENT sid="1" pm="."><plain>Methods: The WARSS compared the efficacy of adjusted-dose <z:chebi fb="8" ids="10033">warfarin</z:chebi> (INR 1.4-2.8) to aspirin (325 mg/day) for recurrent <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or <z:hpo ids='HP_0011420'>death</z:hpo> within 2 years </plain></SENT>
<SENT sid="2" pm="."><plain>The effect of <z:chebi fb="8" ids="10033">warfarin</z:chebi> and aspirin was compared among prespecified and exploratory subgroups with respect to sociodemographic and vascular risk factors, <z:hpo ids='HP_0001297'>stroke</z:hpo> subtype, arterial territory, and <z:mpath ids='MPATH_124'>infarct</z:mpath> topography </plain></SENT>
<SENT sid="3" pm="."><plain>Hazard ratios and 95% confidence intervals comparing <z:chebi fb="8" ids="10033">warfarin</z:chebi> to aspirin were calculated using Cox proportional hazards models </plain></SENT>
<SENT sid="4" pm="."><plain>Differences in hazard ratios were tested using interaction terms </plain></SENT>
<SENT sid="5" pm="."><plain>Results: No treatment differences between <z:chebi fb="8" ids="10033">warfarin</z:chebi> and aspirin were found across multiple prespecified subgroups </plain></SENT>
<SENT sid="6" pm="."><plain>In a multivariate model, <z:chebi fb="8" ids="10033">warfarin</z:chebi> was associated with greater hazard among patients with moderate <z:hpo ids='HP_0001297'>stroke</z:hpo> severity (HR 1.63, 95% CI 1.005-2.64, p = 0.047) and a greater benefit among those with posterior circulation location without <z:e sem="disease" ids="C0521542" disease_type="Disease or Syndrome" abbrv="">brainstem infarction</z:e> (HR 0.54, 95% CI 0.33-0.88, p = 0.013) </plain></SENT>
<SENT sid="7" pm="."><plain>In post-hoc analyses of the cryptogenic subgroup, <z:chebi fb="8" ids="10033">warfarin</z:chebi> was associated with worse outcomes among patients with moderate <z:hpo ids='HP_0001297'>stroke</z:hpo> severity and better outcomes among those without baseline <z:hpo ids='HP_0000822'>hypertension</z:hpo> or with posterior circulation <z:mpath ids='MPATH_124'>infarcts</z:mpath> sparing the brainstem </plain></SENT>
<SENT sid="8" pm="."><plain>Conclusions: In the WARSS, the majority of subgroup analyses showed no benefit of <z:chebi fb="8" ids="10033">warfarin</z:chebi> over aspirin </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> benefit was limited to brainstem-sparing posterior circulation <z:mpath ids='MPATH_124'>infarcts</z:mpath> and select cryptogenic <z:hpo ids='HP_0001297'>stroke</z:hpo> subgroups </plain></SENT>
<SENT sid="10" pm="."><plain>Pending future clinical trial evidence to the contrary, antiplatelets are recommended for survivors of noncardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>